Application Software

Cellebrite DI

Cellebrite DI Federal Business Rebounds, AI Products Drive Annual Recurring Revenue Growth Beyond Expectations

Cellebrite DI Reports Strong Q1 2026 Earnings with 21% ARR Growth, Launches Genesys AI Solution

Cellebrite DI released FY2026 Q1 earnings on May 14 Pre-Market (EST), actual revenue USD 128.3 M (forecast USD 127.03 M), actual EPS USD 0.0399 (forecast USD 0.048)

Cellebrite DI to Release FY2026 Q1 Earnings on May 14 Pre-Market EST, Forecast Revenue USD 127.03 M, EPS USD 0.048

Cellebrite DI Ltd's Chief Product and Technology Officer Submits Initial Beneficial Ownership Statement

Cellebrite Completes Acquisition of SCG Canada, Inc. and Enhances Drone Forensics Capabilities

Cellebrite Reports 21% Growth in Annual Recurring Revenue

Cellebrite DI released FY2025 Q4 earnings on February 11 Pre-Market (EST), actual revenue USD 128.82 M (forecast USD 126.07 M), actual EPS USD 0.0799 (forecast USD 0.0898)

Cellebrite DI released FY2025 annual earnings on February 11 Pre-Market EST, actual revenue USD 475.68 M (forecast USD 472.92 M), actual EPS USD 0.3099 (forecast USD 0.3197)

Cellebrite DI to release FY2025 Q4 earnings on February 11 Pre-Market EST, forecast revenue USD 126.07 M, EPS USD 0.0898

William Blair Maintains Buy Rating on Cellebrite DI

Cellebrite DI Receives a Buy Rating from Bank of America Securities

Cellebrite DI released FY2025 9 Months earnings on November 12 After-Market EST, actual revenue USD 220.83 M, actual EPS USD 0.1501

Cellebrite DI released FY2025 Q3 earnings on November 12 After-Market EST, actual revenue USD 126.03 M (forecast USD 122.98 M), actual EPS USD 0.0799 (forecast USD 0.0879)

Lake Street analyst maintains buy rating on Cellebrite DI

Cellebrite DI to Release FY2025 Q3 Earnings on November 12 After-Market (EST), Forecast Revenue USD 122.98M, EPS USD 0.0885

Cellebrite DI reports Q2 2025 financial results

Cellebrite DI released FY2025 Q2 earnings on August 14 Pre-Market EST, actual revenue USD 113.28 M (forecast USD 112.21 M), actual EPS USD 0.08 (forecast USD 0.0691)

Cellebrite DI released FY2025 Semi-Annual Earnings on August 14 Pre-Market EST, actual revenue USD 220.83 M, actual EPS USD 0.15

Cellebrite DI to release FY2025 Q2 earnings report on August 14, pre-market EST, with forecasted revenue of USD 112.21 M and EPS of USD 0.0691

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

MetaVia

Vida Global

MicroAlgo

Tradr 2X Long XNDU Daily ETF

CLBT

Cellebrite DI (NASDAQ: CLBT) is experiencing renewed growth in government demand and international markets, driven by AI and defense tools. CEO Thomas Hogan noted a rebound in federal business after previous slowdowns, with expectations for annual recurring revenue growth to exceed historical levels. The company highlighted its Genesis AI product and FedRAMP Level 4 authorization as key growth drivers. Additionally, Cellebrite Federal was established to enhance access to U.S. federal agencies, further expanding market opportunities.

Market Beat

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Cellebrite DI Sees Federal Rebound as AI, Defense Tools Fuel New Growth

NVMI

YETI

Wall Street experienced a rally driven by strong earnings from companies like Nova, YETI, Cellebrite, and Dillard's, which exceeded analyst expectations. Additionally, Jerome Powell's tenure as Fed chair concluded, with Kevin Warsh taking over amid a divided Federal Open Market Committee. Meanwhile, ongoing tensions in the Middle East are keeping oil prices high, raising inflation concerns even as markets remain focused on growth and AI advancements.

Nova

Dillards

Yeti

Wall Street rallies on strong earnings and Fed leadership shift

William Blair analyst Jonathan Ho has reiterated a Buy rating on Cellebrite (CLBT), citing strong financial performance, AI-driven product momentum, and expanding margins. The company exceeded revenue and adjusted EBITDA expectations, showing double-digit organic and subscription growth. Ho highlights the strategic potential of products like Genesis and Guardian, along with positive customer feedback and FedRAMP High authorization for federal opportunities. Despite soft near-term revenue guidance, management maintains strong long-term targets, with Ho projecting over 20% upside in the next year. Lake Street also issued a Buy rating with a $21.00 price target.

- Analyst Jonathan Ho from William Blair maintained a bullish stance on CLBT stock, assigning a buy rating.  
- Ho's positive outlook is based on Cellebrite's strong financial performance, growth from new AI-driven products, and positive customer feedback on strategic offerings like Genesis and Guardian.  
- Despite recent guidance showing slight revenue weakness, management reaffirmed strong long-term ARR and EBITDA targets, indicating over 20% upside potential within the next year, supported by continued growth and expansion of valuation multiples.

Tip Ranks

Jonathan Ho Reiterates Buy on Cellebrite, Citing Strong Beat, Expanding Margins and AI-Driven Growth with 20%+ Upside Potential

Cellebrite DI shares are trading higher after the company reported better-than-expected Q1 financial results.

benzinga_article

The Mobile Forensics Market is projected to grow from USD 5.72 billion in 2026 to USD 9.99 billion by 2031, with a CAGR of 11.8%. The demand for rapid evidence turnaround and real-time investigative capabilities is driving this growth. The services segment is expected to hold the largest market share, while the BFSI sector will see the highest growth rate. Asia Pacific is anticipated to register the fastest growth due to increasing smartphone penetration and digital transactions. Key players include Cellebrite, MSAB, and Oxygen Forensics.

prnewswire

10:01 ETMobile Forensics Market worth $9.99 billion by 2031 | MarketsandMarkets™

Cellebrite DI (NASDAQ:CLBT) reported strong Q1 2026 results, with a 21% year-over-year growth in ARR, reaching $493 million, and adjusted EBITDA of $30.6 million, a 29% increase. The company launched its next-gen AI solution, Genesys, currently being tested by over 500 users across 15 countries. Cellebrite received FedRamp High authorization, enhancing its U.S. federal market position, and anticipates a rebound in federal bookings. Management expressed optimism for future growth, leveraging AI and expanding into new markets, with potential revenue doubling.

Cellebrite DI Q1 2026 Earnings Call Transcript

Cellebrite DI Ltd. (NASDAQ: CLBT) reported its first-quarter 2026 results, showcasing a 19% revenue increase to $128.3 million and a 21% growth in Total Annual Recurring Revenue (ARR) to $493.0 million. The company achieved a GAAP net income of $10.9 million and a non-GAAP net income of $30.6 million. Key innovations include the introduction of Cellebrite Genesis, an AI product for investigations, and the acquisition of SCG Canada Inc. to enhance drone forensics capabilities. The company also received FedRAMP® High Authorization for its Government Cloud platform, ensuring compliance with federal security standards.

07:00 ETCellebrite Announces First-Quarter 2026 Results

Cellebrite DI Ltd. (NASDAQ: CLBT) announced its participation in several upcoming investor conferences in May and June 2026. Key events include the J.P. Morgan 2026 Global Technology, Media and Communications Conference on May 18, and the TD Cowen 52nd Annual Technology, Media & Telecom Conference on May 27. Other conferences include the Craig-Hallum Institutional Investor Conference, William Blair 46th Annual Growth Conference, Mizuho Technology Conference 2026, and D.A. Davidson 2026 Technology & Consumer Conference. Access to webcasts for the fireside chats will be available on Cellebrite's investor relations microsite.

StockTitan

Toronto Dominion Bank

Cohen

Cohen & Steers Reit and Pref and Income Fd

Change, Inc. (Japan)

Hallmark Financial

Halliburton

Clear Street

Nano Labs

William Penn Ban

BELLEVUE LIFE SCIENCES ACQ CORP COM USD0.0001 (SUB RIGHTS)

Blackwall Limited

Mizuho Financial

Harley Davidson

Donaldson

G. A. HOLDINGS

Bellevue Life Sciences Acquisition

BELLEVUE LIFE SCIENCES ACQ CORP C/WTS (TO PUR COM)

Bellevue Life Sciences Acquisition - Unit

Mizuho Financial Group, Inc.

Cellebrite Announces Participation in Upcoming Investor Conferences | CLBT Stock News

Cellebrite DI(CLBT.US)